公开(公告)号：US08157846B2

公开(公告)日：2012-04-17

申请号：US12179136

申请日：2008-07-24

Applicant: David S. Randol ,  David A. Walsh

Inventor： David S. Randol ,  David A. Walsh

IPC: A61B17/70

CPC classification number: A61B17/7037 ,  A61B17/7032 ,  A61B2090/037

Abstract: Locking mechanisms and methods of fixation, such as the fixation of a fixation device like a bone screw and of a rod to the spine. The locking mechanism includes a body, a rod seat and a set screw. The rod seat is configured to separate into two pieces when the rod exerts force on the top portion of the washer and the set screw limits movement of the washer toward the bottom of the locking mechanism.

Abstract translation: 锁定机构和固定方法，例如将固定装置如骨螺钉和杆固定到脊柱上。 锁定机构包括主体，杆座和固定螺钉。 当杆在垫圈的顶部施加力时，杆座构造成分成两部分，并且固定螺钉限制垫圈朝向锁定机构的底部的运动。

公开(公告)号：US20110196430A1

公开(公告)日：2011-08-11

申请号：US12703392

申请日：2010-02-10

Applicant: David A. Walsh ,  David S. Randol

Inventor： David A. Walsh ,  David S. Randol

IPC: A61B17/86

CPC classification number: A61B17/7037

Abstract: A novel locking mechanism including a body and intermediate element and a method for locking the relative positions of a rod and a screw. The intermediate element is adapted to receive a rod and a head of a screw and is located between the rod and the head of the screw. The intermediate element has a non-circular shape such that at least one large non-contact area exists when the intermediate element is in contact with the head of the screw and the locking mechanism is fully engaged. The body is adapted to maintain the orientation of the non-circular intermediate element with respect to the body. The body also has at least one structure defining at least one distinct temporary stopping point for the intermediate element above the final locking position.

Abstract translation: 一种包括主体和中间元件的新颖的锁定机构和用于锁定杆和螺钉的相对位置的方法。 中间元件适于容纳杆和螺钉的头部，并且位于杆和螺钉的头部之间。 中间元件具有非圆形形状，使得当中间元件与螺钉的头部接触并且锁定机构完全接合时，存在至少一个大的非接触区域。 身体适于保持非圆形中间元件相对于身体的取向。 该主体还具有至少一个结构，其限定了在最终锁定位置上方的中间元件的至少一个不同的临时停止点。

公开(公告)号：US20100152787A1

公开(公告)日：2010-06-17

申请号：US11816806

申请日：2007-07-26

Applicant: David A. Walsh ,  Carl Arthur Knobloch ,  Daniel R. Baker

Inventor： David A. Walsh ,  Carl Arthur Knobloch ,  Daniel R. Baker

IPC: A61B17/86

CPC classification number: A61B17/7037 ,  A61B17/7002 ,  A61B17/7032

Abstract: A locking mechanism (100) and method of fixation, such as the fixation of a fixation device (104) like a bone screw and of a rod (106) to the spine. The locking mechanism (100) includes a body (102), an insert (108, 308), a rod seat (110, 310) and a set screw. The body (102) includes a bottom portion (114) configured to receive the fixation device (104) and the insert (108, 308) but prevents the insert (108, 308) and fixation device (104) from passing therethrough once the insert (108, 308) and fixation device (104) are engaged. The body (102) further includes a side portion (120) configured to receive the rod (106). Between the rod (106) and the insert (108, 308) is a rod seat (110, 310).

Abstract translation: 锁定机构（100）和固定方法，例如将固定装置（104）如骨螺钉和杆（106）固定到脊柱上。 锁定机构（100）包括主体（102），插入件（108,308），杆座（110,310）和固定螺钉。 本体（102）包括构造成接收固定装置（104）和插入件（108,308）但是防止插入件（108,308）和固定装置（104）穿过其中的底部部分（114），一旦插入件 （108,308）和固定装置（104）接合。 主体（102）还包括构造成容纳杆（106）的侧部（120）。 杆（106）和插入件（108,308）之间是杆座（110,310）。

公开(公告)号：USD543445S1

公开(公告)日：2007-05-29

申请号：US29232486

申请日：2005-06-20

Applicant: James F. Latal ,  Richard J. Tracy ,  Michael B. Grimm ,  Bradley J. Haymond ,  David A. Walsh

Designer： James F. Latal ,  Richard J. Tracy ,  Michael B. Grimm ,  Bradley J. Haymond ,  David A. Walsh

公开(公告)号：US5070087A

公开(公告)日：1991-12-03

申请号：US349247

申请日：1989-05-08

Applicant: Lina C. Teng ,  David A. Walsh ,  James R. Shanklin, Jr.

Inventor： Lina C. Teng ,  David A. Walsh ,  James R. Shanklin, Jr.

IPC: A61K31/40 ,  A61K31/44 ,  A61K31/445 ,  A61K31/55

CPC classification number: A61K31/40 ,  A61K31/44 ,  A61K31/445 ,  A61K31/55

Abstract: A method of treating cardiac dysfunction, the effects of histamine, and gastric secretion excesses with aryl(alkyl and alkylene)-N-[(phenoxy and phenythio)alkyl]aminoheterocyclics corresponding to the formula: ##STR1## wherein Ar is phenyl or substituted phenyl; R is phenyl, substituted phenyl, pyridinyl or cycloalkyl; A is hydrogen, hydroxy, cyano, amido and amino; Q is --CH.sub.2 --, --CH--, or --CHOH--; d and n are zero or one and the dotted lines form double bonds consistent with the valence of carbon; p is zero, one or two; m is one to six inclusive; B is oxygen, nitrogen, sulfur, sulfinyl or sulfonyl; z is zero or one; l is zero or one; W is hydrogen, loweralkyl, halo, nitro, loweralkoxy or hydroxy; X is hydrogen, loweralkyl, halogen, loweralkoxy or hydroxy; Y is --CH(OH)CH.sub.2 OH, --CH(OH)C(O)OH, --C(O)C(O)OH, --C(O)CH.sub.2 OH,--C(O)C(O)OCH.sub.3, --C(O)C(O)OC.sub.2 H.sub.5, --CH.sub.2 C(O)OC.sub.2 H.sub.5, --CH(OH)C(O)OCH.sub.3, --CH(OH)C(O)OC.sub.2 H.sub.5 or --C(O)CH.sub.2 OC(O)CH.sub.3 ; and the pharmaceutically acceptable salts thereof; in addition to the above methods of treatment, compounds wherein (B).sub.z is oxygen are useful in a method of treating Gell and Coombs type 1 allergic responses in mammals.

Abstract translation: 一种治疗心脏功能障碍的方法，组胺和胃分泌过度与芳基（烷基和亚烷基）-N - [（苯氧基和苯基）烷基]氨基杂环对应于下式：其中Ar是苯基或取代的苯基 ; R是苯基，取代的苯基，吡啶基或环烷基; A是氢，羟基，氰基，酰氨基和氨基; Q是-CH 2 - ， - CH-或-CHOH-; d和n为零或一个，虚线形成与碳化合价一致的双键; p为零，一或二; m是一到六个包含; B是氧，氮，硫，亚磺酰基或磺酰基; z为零或一; l为零或一; W是氢，低级烷基，卤素，硝基，低级烷氧基或羟基; X是氢，低级烷基，卤素，低级烷氧基或羟基; Y是-CH（OH）CH 2 OH，-CH（OH）C（O）OH，-C（O）C（O）OH，-C（O）CH 2 OH，-C（O）C（O） C（O）C（O）OC 2 H 5，-CH 2 C（O）OC 2 H 5，-CH（OH）C（O）OCH 3，-CH（OH）C（O）OC 2 H 5或-C（O）CH 2 OC（O） 及其药学上可接受的盐; 除了上述治疗方法之外，其中（B）z是氧的化合物可用于治疗哺乳动物中凝胶和1型过敏反应的方法。

公开(公告)号：US4440785A

公开(公告)日：1984-04-03

申请号：US339211

申请日：1982-01-13

Applicant: David A. Walsh

Inventor： David A. Walsh

IPC: C07D209/34 ,  A61K31/19 ,  C07C149/43

CPC classification number: C07D209/34

Abstract: Novel 2-aminobiphenylacetic acids, esters and metal salts of the formula are disclosed: ##STR1## wherein R represents hydrogen, lower alkyl, sodium or potassium; R.sup.1 represents fluoro, chloro, bromo, lower-alkyl or amino; R.sup.2 represents lower-alkyl, lower-alkoxy, fluoro, chloro, bromo, amino or trifluoromethyl; and m and n are 0-2 with the proviso that when R.sup.1 or R.sup.2 are tertiary butyl or a sterically hindering lower alkyl radical, m and/or n are 1. The compounds are prepared by hydrolysis of 4-(5-, 6- and 7-)phenylindolin-2-ones to give the 2-amino-3-(4-, 5- and 6-)biphenylacetic acids. The free acids are converted to the esters and metal salts. The compounds have anti-inflammatory activity and inhibit blood platelet aggregation.

Abstract translation: 公开了新的2-氨基联苯乙酸，下式的酯和金属盐：其中R代表氢，低级烷基，钠或钾; R1代表氟，氯，溴，低级烷基或氨基; R 2表示低级烷基，低级烷氧基，氟，氯，溴，氨基或三氟甲基; 并且m和n为0-2，条件是当R 1或R 2为叔丁基或空间位阻低级烷基时，m和/或n为1.化合物通过4-（5-， 和7-）苯基吲哚啉-2-酮，得到2-氨基-3-（4-，5-和6-）联苯乙酸。 游离酸转化成酯和金属盐。 该化合物具有抗炎活性并抑制血小板聚集。

公开(公告)号：US4254135A

公开(公告)日：1981-03-03

申请号：US85361

申请日：1979-10-16

Applicant: David A. Walsh ,  Dwight A. Shamblee

Inventor： David A. Walsh ,  Dwight A. Shamblee

IPC: C07D207/14 ,  C07D207/20 ,  C07D491/04 ,  C07D498/04 ,  A61K31/40

CPC classification number: C07D491/04 ,  C07D207/14 ,  C07D207/20

Abstract: Cis and trans 3-amino-4-hydroxypyrrolidines and derivatives thereof are disclosed having the formula: ##STR1## wherein R.sub.1 is hydrogen, loweralkyl or phenylcarbonyl; R.sub.2 is hydrogen, loweralkyl, lowercycloalkyl, phenyl or phenylloweralkyl; R.sub.3 is hydrogen, loweralkyl, phenylloweralkyl, phenylcarbonyl, diphenylmethyl, 5-yl-10,11-dihydro-5H-dibenzo[a,d]cycloheptene or naphthylcarbonyl; R.sub.4 is hydrogen, loweralkyl, phenylloweralkyl or lowercycloalkyl; phenyl is optionally substituted and acid addition salts thereof. The compounds have antidepressant activity and methods and pharmaceutical compositions for use thereof are disclosed.

Abstract translation: 公开了具有下式的顺式和反式3-氨基-4-羟基吡咯烷及其衍生物：其中R 1是氢，低级烷基或苯基羰基; R2是氢，低级烷基，低级环烷基，苯基或苯基低级烷基; R3是氢，低级烷基，苯基低级烷基，苯基羰基，二苯甲基，5-基-10,11-二氢-5H-二苯并[a，d]环庚烯或萘基羰基; R4是氢，低级烷基，苯基低级烷基或低级环烷基; 苯基是任选取代的及其酸加成盐。 该化合物具有抗抑郁活性，并且公开了其用途的方法和药物组合物。

公开(公告)号：US4221716A

公开(公告)日：1980-09-09

申请号：US12698

申请日：1979-02-16

Applicant: Young S. Lo ,  David A. Walsh ,  William J. Welstead, Jr.

Inventor： Young S. Lo ,  David A. Walsh ,  William J. Welstead, Jr.

IPC: A61K31/40 ,  B01J27/16 ,  C07B61/00 ,  C07D209/08 ,  C07D209/30 ,  C07D209/34 ,  C07D209/40

CPC classification number: C07D209/30 ,  C07D209/08 ,  C07D209/34 ,  C07D209/40

Abstract: A novel process for the preparation of 7-acylindolin-2-ones of the formula: ##STR1## wherein R is hydrogen, halogen, lower alkyl, lower alkoxy, or trifluoromethyl; R.sup.1 is lower alkyl, alkylphenyl, cycloalkyl, or aryl; and R.sup.2 is hydrogen, lower alkyl or benzyl is provided. The compounds are useful as intermediates in the preparation of 2-amino-3-acylphenylacetic acid compounds which possess pharmaceutical properties.

Abstract translation: 一种用于制备下式的7-丙烯醛-2-酮的新方法：其中R是氢，卤素，低级烷基，低级烷氧基或三氟甲基; R1是低级烷基，烷基苯基，环烷基或芳基; 并且R2是氢，提供了低级烷基或苄基。 该化合物可用作制备具有药物性质的2-氨基-3-酰基苯基乙酸化合物的中间体。

公开(公告)号：USD537327S1

公开(公告)日：2007-02-27

申请号：US29236055

申请日：2005-08-10

Applicant: Richard J. Tracy ,  David A. Walsh

Designer： Richard J. Tracy ,  David A. Walsh

公开(公告)号：US06946554B2

公开(公告)日：2005-09-20

申请号：US10878035

申请日：2004-06-29

Applicant: Arthur J. Elliott ,  David A. Walsh ,  Philip E. Morris

Inventor： Arthur J. Elliott ,  David A. Walsh ,  Philip E. Morris

IPC: A61K31/519 ,  A61K31/5377 ,  A61K31/541 ,  C07D487/04 ,  C07D207/34

CPC classification number: C07D487/04 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/541

Abstract: Derivatives of 9-deazaguanine of the formula I: are prepared by reacting an aldehyde or ketone of the formula II: with a dialkylaminomalonate to produce an enamine. The enamine is then reacted with a base to produce a pyrrole represented by the formula: The pyrrole is reacted with a compound represented by the formula R3OC(O)N═C(Z)NHC(O)OR3 or a derivative of carbamimidoic acid to provide a protected guanidine compound. The guanidine compound is converted to the desired deazaguanine by reaction with 1) trifluoracetic acid or 2) C1-C4 alkoxide or alkali metal or alkaline earth metal hydroxide followed by neutralization with an acid.

Abstract translation: 式I的9-脱氮鸟嘌呤的衍生物通过使式II的醛或酮与二烷基氨基马来酸盐反应以制备烯胺来制备。 然后将烯胺与碱反应以产生由下式表示的吡咯：吡咯与由式R 3 OC（O）NC（Z）NHC（O）OR表示的化合物反应 3或氨基甲脒酸的衍生物，以提供受保护的胍化合物。 胍化合物通过与1）三氟乙酸或2）C 1 -C 4烷醇盐或碱金属或碱土金属氢氧化物反应而转化为所需的脱氮鸟嘌呤，随后中和 与酸。